Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.

导出 LinkOut

翻译打印收藏纠错

作者： Jing,Zhang ^[1] ; Yan,Wang ^[2] ; Shu-Qi,Li ^[3] ; Le,Fang ^[4] ; Xiao-Zhong,Wang ^[5] ; Jing,Li ^[1] ; Hai-Bin,Zhang ^[2] ; Bo,Huang ^[6] ; Yan-Mei,Xu ^[1] ; Wei-Ming,Yang ^[2] ; Jin,Lin ^[7] ; Qing-Hua,Min ^[1] ; Zhi-Hua,Liao ^[2] ; Yan,Wu ^[1] ; Jing,Liu ^[2]

作者单位： Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China. ^[1] Jiangxi Province Key Laboratory of Laboratory Medicine, Nanchang, China. ^[2] Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China. ^[3] Key Laboratory of Hematological Disease Diagnostic, Treat Centre of Guizhou Province, Guiyang, China. ^[4] Department of Hematology, Guizhou Provincial Laboratory of Hematopoietic Stem Cell Transplantation Center, Guiyang, China. ^[5] Department of Clinical Laboratory, 521 Hospital of Ordnance Industry, Xi'an, China. ^[6] Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, China. ^[7] Department of Clinical Laboratory, Jiangxi Maternal and Child Health Care Hospital, Nanchang, China. ^[8] Center for Disease Control and Prevention of Donghu District, Nanchang, China. ^[9]

关键词 Bcl-x IMATINIB chronic myeloid leukaemia splicing